BridgeBio Oncology Therapeutics Inc. announced late-breaking preclinical data on BBO-10203, a first-in-class covalent small molecule RAS:PI3Kα breaker, at the San Antonio Breast Cancer Symposium (SABCS). The preclinical data demonstrated that BBO-10203 blocks RAS-mediated activation of PI3Kα, inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows anti-tumor activity both as monotherapy and in combination with standard therapies in breast cancer models. The company also presented information regarding the Phase 1 BREAKER-101 clinical trial (NCT06625775), which is currently enrolling patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer in the United States and Australia. Initial Phase 1 clinical data from the BREAKER-101 trial are expected in the first half of 2026.